Adam P. Dicker mainly investigates Radiation therapy, Internal medicine, Prostate cancer, Oncology and Surgery. His research in Radiation therapy intersects with topics in Androgen deprivation therapy and Nuclear medicine. His Prostate cancer study integrates concerns from other disciplines, such as Prostate, MEDLINE and Bioinformatics.
His Oncology research integrates issues from Cancer, Metastasis, Clinical trial, Multivariate analysis and Cohort. His Cancer research includes elements of Cancer research and Angiogenesis. His Surgery research is multidisciplinary, relying on both Glioma, Radiology and Varicocele.
Adam P. Dicker mainly focuses on Internal medicine, Oncology, Prostate cancer, Radiation therapy and Cancer research. Internal medicine and Surgery are frequently intertwined in his study. His Oncology research includes themes of Cervical cancer, Metastasis, Chemotherapy and Hazard ratio.
His Prostate cancer research is multidisciplinary, incorporating elements of Prostate and Randomized controlled trial. Adam P. Dicker interconnects Medical physics, Nuclear medicine and Pathology in the investigation of issues within Radiation therapy. Adam P. Dicker has researched Cancer research in several fields, including Apoptosis, Immunology and Epidermal growth factor receptor.
Adam P. Dicker mostly deals with Internal medicine, Oncology, Prostate cancer, Radiation therapy and Cancer. Many of his research projects under Internal medicine are closely connected to SABR volatility model with SABR volatility model, tying the diverse disciplines of science together. His Oncology study combines topics in areas such as Hazard ratio, Metastasis, Surgery and Immunotherapy.
His research investigates the connection between Prostate cancer and topics such as Prostate that intersect with problems in Androgen receptor. His work on Radiosurgery is typically connected to In patient as part of general Radiation therapy study, connecting several disciplines of science. His research investigates the connection between Cancer and topics such as Cancer research that intersect with issues in Immune system.
Adam P. Dicker focuses on Internal medicine, Oncology, Prostate cancer, Radiation therapy and Prostatectomy. His Internal medicine research incorporates themes from Artificial neural network and DECIPHER. The concepts of his Oncology study are interwoven with issues in Surgery, MEDLINE, Metastasis, Hazard ratio and Genetic testing.
His Prostate cancer research is multidisciplinary, incorporating perspectives in Prostate and Retrospective cohort study. His studies in Radiation therapy integrate themes in fields like Clinical endpoint, Clinical trial, Randomized controlled trial, Lung cancer and Immunotherapy. The various areas that Adam P. Dicker examines in his Prostatectomy study include Bioinformatics, Gene expression profiling, Proportional hazards model, Prostate-specific antigen and Cohort.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
Lowell E. Schnipper;Nancy E. Davidson;Dana S. Wollins;Courtney Tyne.
Journal of Clinical Oncology (2015)
Microsurgical inguinal varicocelectomy with delivery of the testis: an artery and lymphatic sparing technique.
Marc Goldstein;Bruce R. Gilbert;Adam P. Dicker;Jack Dwosh.
The Journal of Urology (1992)
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
Peter Grimm;Ignace Billiet;David Bostwick;Adam P Dicker.
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
Lowell E. Schnipper;Nancy E. Davidson;Dana S. Wollins;Douglas W. Blayney.
Journal of Clinical Oncology (2016)
Zebrafish: an emerging model system for human disease and drug discovery.
G Kari;U Rodeck;A P Dicker.
Clinical Pharmacology & Therapeutics (2007)
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial
Ryan Phillips;William Yue Shi;Matthew Deek;Noura Radwan.
JAMA Oncology (2020)
Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
James J. Farrell;Hany Elsaleh;Miguel Garcia;Raymond Lai.
Dihydrofolate reductase as a therapeutic target.
Barry I. Schweitzer;Adam P. Dicker;Joseph R. Bertino.
The FASEB Journal (1990)
Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.
Phyllis Wachsberger;Randy Burd;Adam P. Dicker.
Clinical Cancer Research (2003)
Differentiation and definition of vascular-targeted therapies.
Dietmar W. Siemann;Michael C. Bibby;Graham G. Dark;Adam P. Dicker.
Clinical Cancer Research (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: